eftansomatropin alfa
Recombinant proteinexperimental
Clinical trial activity
5 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started Jan 1, 2015 (NCT02946606)
Timeline
Indications
Mechanism of action
- Growth hormone receptorAGONIST
GHR agonist
- SomatotropinSupplementation
GH1 supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- gx-h9
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07300436 | Phase 1 | Jan 31, 2026 | — |
| NCT07181473 | Phase 1 | Aug 25, 2025 | Phrontline Biopharma |
| NCT04633057 | Phase 3 | Jan 25, 2021 | I-Mab Biopharma |
| NCT03309891 | Phase 2 | Dec 31, 2016 | Genexine, Inc. |
| NCT02946606 | Phase 2 | Jan 1, 2015 | Genexine, Inc., Yonsei University |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Genexine, Inc. | For profit | 2 | 2 | 1 | 2015 |
| I-Mab Biopharma | For profit | 1 | 1 | 1 | 2021 |
| Phrontline Biopharma | For profit | 1 | 1 | 1 | 2025 |
| Yonsei University | Academic/Hospital | 1 | 0 | 1 | 2015 |
4 organizations
Page 1 / 1